2023 World Conference on Lung Cancer (Posters)-EP13.05. Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma

EP13.05. Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma - PDF(Slides)

Back to course

Pdf Summary

This is a summary of a study that assessed the real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma (PNEC). PNEC is a type of lung cancer characterized by poor prognosis. The study enrolled 203 patients treated with PD-1/PD-L1 inhibitors at Zhejiang Cancer Hospital in China. The patients were evaluated for objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). <br /><br />The study found that PD-1/PD-L1 inhibitors were effective in advanced PNEC patients in the real-world setting. The efficacy of first-line (1L) immunochemotherapy was notable, with an ORR of 65.6% and a DCR of 92.8%. In the second-line or later line (2L) setting, the median PFS was 4.0 months and median OS was 9.4 months. <br /><br />Additionally, the study compared the outcomes among patients with different histologies and found no significant difference in PFS and OS between patients with small cell lung cancer (SCLC), pulmonary large-cell neuroendocrine carcinoma (LCNEC), and unspecified PNEC. Patients without liver metastases showed a significantly longer PFS and OS compared to those with liver metastases.<br /><br />The study also evaluated the efficacy of different treatment regimens and found that pretreated patients with PD-1/PD-L1 inhibitors plus small-molecule antiangiogenic therapy had a significantly greater PFS than those with PD-1/PD-L1 inhibitors monotherapy or PD-1/PD-L1 inhibitors plus chemotherapy.<br /><br />In conclusion, this study suggests that PD-1/PD-L1 inhibitors are effective in advanced PNEC patients in a real-world setting. The addition of small-molecule antiangiogenic therapy to immunotherapy in 2L treatment showed a better survival trend. Further studies are needed to confirm these findings.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

PD-1/PD-L1 inhibitors

advanced pulmonary neuroendocrine carcinoma

lung cancer

real-world efficacy

immunochemotherapy

progression-free survival

overall survival

small cell lung cancer

large-cell neuroendocrine carcinoma

antiangiogenic therapy